Sanjiv Sam Gambhir, M.D., Ph.D.
Dr. Sanjiv Sam Gambhir is Director of the Molecular Imaging Program (MIPS) at Stanford University, Professor in the Department of Radiology and Bio-X Program and Head of Nuclear Medicine at Stanford University School of Medicine. Internationally regarded as a leader in the field of molecular imaging, Dr. Gambhir’s research and clinical development has transformed the field of nuclear medicine, PET and optical imaging as represented in over 250 peer reviewed publications. Dr. Gambhir has been recognized by the Society of Nuclear Medicine through several prestigious scientific awards, including the Aebersold Award and the Hounsfield Medal Award.
Steven M. Larson, M.D.
Dr. Steven Larson is the Chief of Nuclear Medicine, Head of the Nuclear Medicine Laboratory and member of the Executive Council for the Molecular Pharmacology and Therapeutics program at Memorial Sloan Kettering Cancer Center. Recognized both academically and in government circles for his scientific and FDA-advisory roles, Dr. Larson has been a major influence in the way radiopharmaceuticals are developed in humans and animals. He is a recipient of the Hevesy Award from the Society of Nuclear Medicine, Researcher of the Year from the Radiological Society of North America and the Wiley Medal from the FDA for distinguished service.
Dan Shochat, Ph.D.
Dr. Dan Shochat is Vice President of Nonclinical Development at KaloBios Pharmaceuticals Inc., a biopharmaceutical company specializing in the development of therapeutic antibodies. Dr. Shochat has over 24 years of experience in the biotechnology industry and is a pioneer in the antibody development arena. He has led groups involved with the development of several antibody based therapeutic and imaging agents including the in vivo tumor-imaging agent CEA-Scan, the first approved antibody-cytotoxic drug conjugate Mylotarg, and the radioiodinated antibody Bexxar for the treatment of Non-Hodgkin’s Lymphoma. Dr. Shochat is a past member of the Technical Advisory Committee for the Australian Nuclear Science and Technology Organization and has held faculty appointments at the University of Medicine and Dentistry of New Jersey and Rutgers University Graduate School. Dr. Shochat also acts as a consultant and a member of the scientific advisory boards of several biopharmaceutical companies and venture capital funds.